CD274 and neoplasm: The absence or dysfunction of tumor-infiltrating lymphocytes (TILs) hampers the response to immunotherapy, emphasizing the significance of immune checkpoints, such as PD-1/PD-L1 interactions and the need for therapies that consider the complexity of the TME and its role in immunosuppression within GBMs [8, 11–14].